Non-Small Cell Lung Cancer New Reference: Zongertinib for her2 Mutated NSCLC Ulas D. Bayraktar, MD 2025-05-05
Non-Small Cell Lung Cancer New Reference: Taletrectinib for ROS1-Positive NSCLC Ulas D. Bayraktar, MD 2025-04-22
Non-Small Cell Lung Cancer New Reference: Afatinib for NSCLC with Uncommon EGFR Mutations Ulas D. Bayraktar, MD 2025-04-22
Non-Small Cell Lung Cancer New Indication: Nivolumab – Ipilimumab for Neoadjuvant NSCLC Ulas D. Bayraktar, MD 2025-04-22
Non-Small Cell Lung Cancer New Indication: Datopotamab Deruxtecan in NSCLC with Actionable Mutations Ulas D. Bayraktar, MD 2025-03-31
Non-Small Cell Lung Cancer New Drug: Ivonescimab for PD-L1 Positive NSCLC Ulas D. Bayraktar, MD 2025-03-14
Non-Small Cell Lung Cancer New Protocol: Osimertinib with Ramucirumab for EGFR-Mutated NSCLC Ulas D. Bayraktar, MD 2025-03-02
Non-Small Cell Lung Cancer New Reference: Zenocutuzumab for NRG1 Fusion-Positive Cancer Ulas D. Bayraktar, MD 2025-02-07
Non-Small Cell Lung Cancer Pancreatic Cancer New Drug: Zenocutuzumab for advanced NRG1 fusion positive NSCLC and Pancreatic Cancer Ulas D. Bayraktar, MD 2024-12-06
Non-Small Cell Lung Cancer New Indication: Osimertinib after Chemoradiotherapy in NSCLC Ulas D. Bayraktar, MD 2024-09-30
